Related Experiment Video
Updated: May 31, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
1Institute of Neuroimmunology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Abstract:
Mitoxantrone is an anthracenedione antineoplastic agent approved as an escalating immunotherapy for multiple sclerosis. Owing to structural similarity with other anthracyclines, cardiotoxicity is a severe side effect of mitoxantrone. The risk of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis increases with cumulative doses >100 mg/m(2) body surface area (BSA). However, the effect of mitoxantrone on cardiac function in the early phase of treatment with cumulative doses <100 mg/m(2) BSA is unclear. The present report concerns four patients with a temporary and considerable decrease in left ventricular ejection fraction (LVEF) and with additional echocardiographic findings of diastolic dysfunction after only one or two doses of mitoxantrone. The risk of cardiotoxicity at low doses of mitoxantrone is highlighted.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Mitral Stenosis I: Introduction
Multiple Sclerosis l: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy IV: Restrictive Cardiomyopathy